TIDMPFZ
RNS Number : 8239G
BlackRock Group
24 November 2015
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing BlackRock, Inc.
(Note 1)
========================== ====================
Company dealt in Pfizer, Inc.
========================== ====================
Class of relevant security US$0.05 common stock
to which the dealings
being disclosed relate
(Note 2)
========================== ====================
Date of dealing 23 November 2015
========================== ====================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
=========================== ====================== =====================
Number (%) Number (%)
=========================== ========= ==== ===== ========= ==== ====
395,701,728
(1) Relevant securities (6.41%) 516,078 (0.00%)
=========================== ====================== =====================
(2) Derivatives (other
than options) 1,362,576 (0.02%) 11,021 (0.00%)
=========================== ====================== =====================
(3) Options and agreements 21,200,800
to purchase/sell 20,000,000 (0.32%) (0.34%)
=========================== ====================== =====================
417,064,304 21,727,899
Total (6.76%) (0.35%)
=========================== ====================== =====================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
============================ =================== =====================
Number (%) Number (%)
============================ ======= ==== ==== ========= ==== ====
(1) Relevant securities
============================ =================== =====================
(2) Derivatives (other
than options)
============================ =================== =====================
(3) Options and agreements
to purchase/sell
============================ =================== =====================
Total
============================ =================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(Note 5)
=============== ====================================== ====================
Purchase 42,792 USD 31.3300
=============== ====================================== ====================
Purchase 5,000 USD 31.4000
=============== ====================================== ====================
Purchase 530,116 USD 31.4277
=============== ====================================== ====================
Purchase 213,044 USD 31.4381
=============== ====================================== ====================
Purchase 4,403 USD 31.5228
=============== ====================================== ====================
Sale 417,113 USD 31.2772
=============== ====================================== ====================
Sale 73,490 USD 31.3300
=============== ====================================== ====================
Sale 38,100 USD 31.3526
=============== ====================================== ====================
Please note: there was also a Transfer In of 176,474 Shares.
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
========= ===================== ================== ===========
CFD Reducing Long 761 USD 31.2795
========= ===================== ================== ===========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
========== ============ ============== ======== =============== ====== ====================
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
================= =========================== ===================
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
===================== ============== ====================
Return of stock 32,700 N/A
on loan
===================== ============== ====================
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none,
this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure 24 November 2015
============================ ================
Contact name Tim Dudley
============================ ================
Telephone number +44 20 7743 1540
============================ ================
If a connected EFM, name
of offeree/offeror with
which connected
============================ ================
If a connected EFM, state
nature of connection (Note
10)
============================ ================
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form
8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product Written, Number of relevant Exercise Type, e.g. Expiry
name, or purchased securities price American, date
e.g. call to which the (Note European
option option or derivative 2) etc.
relates
=========== ============== ====================== =========== ========== ==========
Call Option Written 110,200 USD 34.0000 American 04/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Written 186,000 USD 34.5000 American 04/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Purchased 20,000,000 USD 34.5000 American 04/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Written 299,400 USD 35.0000 American 04/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Written 270,000 USD 34.0000 American 18/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Written 110,200 USD 35.0000 American 18/12/2015
=========== ============== ====================== =========== ========== ==========
Call Option Written 20,000,000 USD 37.5000 American 15/01/2016
=========== ============== ====================== =========== ========== ==========
Call Option Written 225,000 USD 34.0000 American 15/01/2016
=========== ============== ====================== =========== ========== ==========
Notes
1. Where there are open option positions or open derivative
positions (except for CFDs), full details should be given. Full
details of any existing agreements to purchase or to sell must also
be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the
Rules. If in doubt, consult the Panel.
This information is provided by RNS
(MORE TO FOLLOW) Dow Jones Newswires
November 24, 2015 10:19 ET (15:19 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Oct 2024 to Nov 2024
Pfizer (LSE:PFZ)
Historical Stock Chart
From Nov 2023 to Nov 2024
